Peptide market reaches $50–60 billion as GLP-1s drive growth

The Peptide Alliance says the global peptide market has grown to $50–60 billion, with about $40 billion now tied to GLP-1 drugs like semaglutide and tirzepatide. The group also released ranked indexes of top influencers and conferences built from its verified directory of 306 suppliers.

Why it matters: - The peptide market is now large enough to be shaped by GLP-1 drugs in a way that affects patients, clinicians, suppliers and investors. - The shift away from compounded semaglutide and toward regulated, late-stage therapies signals a more consolidated market around legitimacy and compliance. - The report’s new rankings aim to give the industry a shared reference point for trusted voices and major events.

What happened: - The Peptide Alliance released The State of Peptides 2026 (H1 Edition) on July 22, 2026. - The report estimates the global peptide market at $50 billion to $60 billion. - Roughly $40 billion of that total is driven by GLP-1 drugs such as semaglutide and tirzepatide. - The Peptide Alliance also published The Top Peptide Influencers and The Top Peptide Conferences. - The rankings are based on a published, weighted methodology and the group’s verified directory of 306 active suppliers.

The details: - The report says an estimated 1 in 8 U.S. adults has used a GLP-1 medication. - The report says the compounded-semaglutide market contracted about 90% year over year after regulatory changes. - The report says retatrutide advanced through Phase 3 after posting about 24.2% mean body-weight reduction in trials. - The top conference ranking is led by TIDES USA, the A4M/MMI Annual World Congress and the Peptide World Congress. - The verified directory includes clinics, compounding pharmacies, brands, research labs and manufacturers. - The full report is available free at peptidealliance.io/state-of-peptides.

Between the lines: - The Peptide Alliance is positioning itself as a data source for a market that has expanded faster than consistent information about it. - The directory-backed rankings create a way to measure influence and event importance in a field that can be fragmented and promotional. - The emphasis on verification suggests the market is moving from hype toward more structured standards.

What's next: - The Peptide Alliance will continue publishing its biannual State of Peptides report. - The organization will maintain its ranked indexes of peptides, influencers and conferences. - Market attention is likely to stay centered on GLP-1 therapies and next-generation candidates such as retatrutide.

The bottom line: - Peptides are no longer a niche category. GLP-1 drugs now dominate the market, and the industry is trying to organize around verified data and credibility.